Cargando…

Clinicopathological and survival outcomes of 4L lymph node dissection in left lung adenocarcinoma and squamous cell carcinoma

BACKGROUND: Whether 4L lymph node dissection (LND) should be performed remains unclear and controversial. Prior studies have found that station 4L metastasis was not rare and that 4L LND may provide survival benefits. The objective of this study was to analyze the clinicopathological and survival ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Leilei, Guo, Juntang, Zhang, Weidong, Liang, Chaoyang, Chen, Han, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126266/
https://www.ncbi.nlm.nih.gov/pubmed/37114135
http://dx.doi.org/10.3389/fonc.2023.1124014
_version_ 1785030202249707520
author Shen, Leilei
Guo, Juntang
Zhang, Weidong
Liang, Chaoyang
Chen, Han
Liu, Yang
author_facet Shen, Leilei
Guo, Juntang
Zhang, Weidong
Liang, Chaoyang
Chen, Han
Liu, Yang
author_sort Shen, Leilei
collection PubMed
description BACKGROUND: Whether 4L lymph node dissection (LND) should be performed remains unclear and controversial. Prior studies have found that station 4L metastasis was not rare and that 4L LND may provide survival benefits. The objective of this study was to analyze the clinicopathological and survival outcomes of 4L LND from the perspective of histology. METHODS: This retrospective study included 74 patients with squamous cell carcinoma (SCC) and 84 patients diagnosed with lung adenocarcinoma (ADC) between January 2008 and October 2020. All patients underwent pulmonary resection with station 4L LND and were staged as T1-4N0-2M0. Clinicopathological features and survival outcomes were investigated based on histology. The study endpoints were disease-free survival (DFS) and overall survival (OS). RESULTS: The incidence rate of station 4L metastasis was 17.1% (27/158) in the entire cohort, with 8.1% in the SCC group, and 25.0% in the ADC group. No statistical differences in the 5-year DFS rates (67.1% vs. 61.7%, P=0.812) and 5-year OS rates (68.6% vs. 59.3%, P=0.100) were observed between the ADC group and the SCC group. Multivariate logistic analysis revealed that histology (SCC vs. ADC: OR, 0.185; 95% CI, 0.049–0.706; P=0.013) was independently associated with 4L metastasis. Multivariate survival analysis showed that the status of 4L metastasis was an independent factor for DFS (HR, 2.563; 95% CI, 1.282–5.123; P=0.008) but not for OS (HR, 1.597; 95% CI, 0.749–3.402; P=0.225). CONCLUSION: Station 4L metastasis is not rare in left lung cancer. Patients with ADC have a greater predilection for station 4L metastasis and may benefit more from performing 4L LND.
format Online
Article
Text
id pubmed-10126266
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101262662023-04-26 Clinicopathological and survival outcomes of 4L lymph node dissection in left lung adenocarcinoma and squamous cell carcinoma Shen, Leilei Guo, Juntang Zhang, Weidong Liang, Chaoyang Chen, Han Liu, Yang Front Oncol Oncology BACKGROUND: Whether 4L lymph node dissection (LND) should be performed remains unclear and controversial. Prior studies have found that station 4L metastasis was not rare and that 4L LND may provide survival benefits. The objective of this study was to analyze the clinicopathological and survival outcomes of 4L LND from the perspective of histology. METHODS: This retrospective study included 74 patients with squamous cell carcinoma (SCC) and 84 patients diagnosed with lung adenocarcinoma (ADC) between January 2008 and October 2020. All patients underwent pulmonary resection with station 4L LND and were staged as T1-4N0-2M0. Clinicopathological features and survival outcomes were investigated based on histology. The study endpoints were disease-free survival (DFS) and overall survival (OS). RESULTS: The incidence rate of station 4L metastasis was 17.1% (27/158) in the entire cohort, with 8.1% in the SCC group, and 25.0% in the ADC group. No statistical differences in the 5-year DFS rates (67.1% vs. 61.7%, P=0.812) and 5-year OS rates (68.6% vs. 59.3%, P=0.100) were observed between the ADC group and the SCC group. Multivariate logistic analysis revealed that histology (SCC vs. ADC: OR, 0.185; 95% CI, 0.049–0.706; P=0.013) was independently associated with 4L metastasis. Multivariate survival analysis showed that the status of 4L metastasis was an independent factor for DFS (HR, 2.563; 95% CI, 1.282–5.123; P=0.008) but not for OS (HR, 1.597; 95% CI, 0.749–3.402; P=0.225). CONCLUSION: Station 4L metastasis is not rare in left lung cancer. Patients with ADC have a greater predilection for station 4L metastasis and may benefit more from performing 4L LND. Frontiers Media S.A. 2023-04-11 /pmc/articles/PMC10126266/ /pubmed/37114135 http://dx.doi.org/10.3389/fonc.2023.1124014 Text en Copyright © 2023 Shen, Guo, Zhang, Liang, Chen and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Shen, Leilei
Guo, Juntang
Zhang, Weidong
Liang, Chaoyang
Chen, Han
Liu, Yang
Clinicopathological and survival outcomes of 4L lymph node dissection in left lung adenocarcinoma and squamous cell carcinoma
title Clinicopathological and survival outcomes of 4L lymph node dissection in left lung adenocarcinoma and squamous cell carcinoma
title_full Clinicopathological and survival outcomes of 4L lymph node dissection in left lung adenocarcinoma and squamous cell carcinoma
title_fullStr Clinicopathological and survival outcomes of 4L lymph node dissection in left lung adenocarcinoma and squamous cell carcinoma
title_full_unstemmed Clinicopathological and survival outcomes of 4L lymph node dissection in left lung adenocarcinoma and squamous cell carcinoma
title_short Clinicopathological and survival outcomes of 4L lymph node dissection in left lung adenocarcinoma and squamous cell carcinoma
title_sort clinicopathological and survival outcomes of 4l lymph node dissection in left lung adenocarcinoma and squamous cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126266/
https://www.ncbi.nlm.nih.gov/pubmed/37114135
http://dx.doi.org/10.3389/fonc.2023.1124014
work_keys_str_mv AT shenleilei clinicopathologicalandsurvivaloutcomesof4llymphnodedissectioninleftlungadenocarcinomaandsquamouscellcarcinoma
AT guojuntang clinicopathologicalandsurvivaloutcomesof4llymphnodedissectioninleftlungadenocarcinomaandsquamouscellcarcinoma
AT zhangweidong clinicopathologicalandsurvivaloutcomesof4llymphnodedissectioninleftlungadenocarcinomaandsquamouscellcarcinoma
AT liangchaoyang clinicopathologicalandsurvivaloutcomesof4llymphnodedissectioninleftlungadenocarcinomaandsquamouscellcarcinoma
AT chenhan clinicopathologicalandsurvivaloutcomesof4llymphnodedissectioninleftlungadenocarcinomaandsquamouscellcarcinoma
AT liuyang clinicopathologicalandsurvivaloutcomesof4llymphnodedissectioninleftlungadenocarcinomaandsquamouscellcarcinoma